TrialCancer research and treatment2026

Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study.

Se Hoon Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.